• Blog
  • Nanomedicine Market Analysis | 2022-2028

    Nanomedicine Market Analysis | 2022-2028

    Nanomedicine Market Analysis | 2022-2028
    Report code - SR2287 Delivery - 2 Weeks
    Nanomedicine Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth Opportu See more...

    “The Nanomedicine Market was estimated at US$ 209 billion in 2021 and is expected to grow at a CAGR of 12.91% during 2022-2028 to reach US$ 523 billion in 2028”.

    Wish to get a free sample? Register Here

    Market Dynamics

    Introduction

    Nanomedicine refers to the application of nanotechnology, involving the manipulation and control of materials at the nanoscale (typically ranging from 1 to 100 nanometers), for diagnosing, treating, and preventing diseases. By exploiting unique properties at this small scale, nanomedicine aims to enhance drug delivery, imaging, and therapy precision, enabling more targeted and effective medical interventions.

    This interdisciplinary field integrates biology, chemistry, physics, and engineering to create innovative solutions that improve drug efficacy, reduce side effects, and enable early disease detection. Nanomedicine holds promise for revolutionizing healthcare by offering personalized and minimally invasive approaches to medical challenges.

    Market Drivers

    The market for nanomedicines is anticipated to be driven by the development and commercialization of procedures that have the potential to improve drug administration and disease management considerably. The expansion of the nanomedicine market has also been fueled by the increasing use of drug delivery techniques based on nanotechnology and the ineffectiveness of conventional treatments in the treatment of diseases.

    In the coming years, it is projected that the usage of nanoparticles in various healthcare contexts will encourage growth. These molecules' ability to bind to chemical moieties in the form of scaffolds allows them to perform a range of jobs. The utilization of nanoparticles for selective binding by affixing them to ligands of cell receptors is one of the main methods used in nanotechnology. It will therefore spur market expansion.

    Additionally, it is projected that the active involvement of well-known pharmaceutical corporations in the creation of cutting-edge treatments based on nanoscience would have an impact on the development of this industry. Additionally, developments in nanotechnology and their expanding applications in preventive interventions, early disease diagnosis, prevention of chronic as well as acute disorders, and prophylaxis of chronic as well as acute disorders are the factors anticipated to propel the growth of the nanomedicine industry. Due to the rising demand for nanomedicines, manufacturers are profiting from tremendous growth potential in the global market. Nanomedicine is expanding in the healthcare industry and is being used increasingly frequently in clinical and healthcare settings. Additionally, it is anticipated that well-known pharmaceutical firms' active participation in the creation of innovative nanoscience-based medications will boost market growth.

    Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

    • Government agencies are projected to expand their R&D spending, creating enticing possibilities for the growth of the nanomedicine market. Massive capital-intensive projects can be accelerated with the help of government funding. For instance, to enhance nanoscale engineering, science, and technology, the National Science Foundation announced in August 2020 that it will invest a total of USD 84 million over five years in re-establishing the National Nanotechnology Coordinated Infrastructure.
    • Additionally, the Canadian government funds research in the fields of nanomedicine and regenerative medicine at the Canadian Institutes of Health Research (CIHR) and the Canadian Space Agency (CSA). As a result, it will fuel the growth of the nanomedicine industry in the upcoming years.

    Recent Mergers & Acquisitions

    To increase their market position, key companies in this market are putting several tactics into practice, such as partnerships through mergers and acquisitions, geographic expansion, and strategic collaborations.

    • In January 2022, NaNotics LLC and Mayo Clinic announced their research partnership to develop a NaNot that selectively targets the soluble form of the immune inhibitor PD-L1, which is produced by tumors.
    • In October 2020, as a result of reaching a pre-clinical milestone successfully, Advanced NanoTherapies, Inc., a privately held medical device company dedicated to investigating nanotechnology for enhanced drug uptake and sustained retention, closed on the final tranche of its seed-round financing for a total of USD 5.3 million. Various angel investment sources in the US, Canada, Europe, Asia, and the Middle East provided funds, as did the Cleveland Clinic and Taiwan's ForMed Ventures.

    Segments Analysis

    Segmentations

    List of Sub-Segments

    Dominant and Fastest-Growing Segments

    Product-Type Analysis

    Nanoparticles, Nanoshells, Nanotubes, and Nanodevices

     

    The nanoparticles market segment had the largest market share in 2021.

     

     

    Application-Type Analysis

     

    Therapeutics, Active Implants, in-vitro Diagnostics, Drug Delivery, In-vivo Imaging, Implants, and Others

    The therapeutics segment will have a considerable growth rate over the projection period.

    Indication-Type Analysis

    Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, and Others

     

    The clinical oncology segment will lead the nanomedicine market during the forecast period.

     

    Regional Analysis

    North America, Europe, Asia-Pacific, and Rest of the World

     

    North America dominated the market in 2021 with the highest share.

     

     

    By Product Type

    “Nanoparticles dominated the market in 2021 and showed the fastest growth rate throughout the forecast period”.

    The market has been segmented into nanoparticles, nanoshells, nanotubes, and nanodevices. The nanoparticles segment is further divided into metal & metal oxide nanoparticles, liposomes, polymers & polymer-drug conjugates, hydrogel nanoparticles, dendrimers, and inorganic nanoparticles.

    The market segment for nanoparticles had the largest market share in 2021 and experienced the quickest growth rate throughout the projected period. The expanding use of metal and metal oxide particles in photodynamic therapy (PDT) for the treatment of cancer and infectious disorders as well as the advantages of various nanoparticles have increased product demand and significant market growth.

    By Application Type

    “The therapeutics segment is expected to experience significant growth rates”.

    The nanomedicine market has been divided into therapeutics, active implants, in-vitro diagnostics, drug delivery, in-vivo imaging, and implants, among others. Due to the large number of products that fall under this category and are used to treat a wide range of disorders, it is projected that the therapeutics segment will have a considerable growth rate. Drug delivery systems, equipment, and pharmaceuticals all fall under this category.

    The development of Nanotherapeutics that can penetrate biological barriers made possible by technological improvements is another factor that is projected to propel the nanomedicine market during the forecast period. Increasing rates of diseases like cancer and the COVID-19 virus, as well as expanding public knowledge of the potential applications for nanomedicines, had a substantial impact on the entire industry in 2021. Additionally, the advancement of reticule-endothelial system evasion, vivo dispersion, and favorable pharmacokinetics will be responsible for the efficiency of nanotechnology in drug delivery, driving segment growth.

    Want to get more details about the segmentations? Register Here

    By Indication Type

    “Clinical oncology led the nanomedicine market”.

    The market is segmented into clinical oncology, infectious diseases, clinical cardiology, orthopedics, and others. The nanomedicine market was led by the clinical oncology sector. The enormous variety of cancer therapy products currently in the clinical phases of development as well as advancements in the introduction of theranostic particles and devices are related to the rising prevalence of cancer illnesses. The technique can be applied as a tool for both active and passive cancer targeting, which will spur market expansion.

    One of the main things driving clinical oncology R&D is the demand for more tailored cancer medicines. Due to its effectiveness in targeting and lack of side effects when treating cancer, nanomedicine is a therapy method that is quickly evolving. The primary preclinical and clinical use of nanomedicine is to target a wide range of diseases and tumors.

    Regional Analysis

    “North America led in 2021 and is projected to maintain its global industry dominance”.

    The nanomedicine market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). With the highest share in 2021, North America dominated the global industry. The region is anticipated to maintain its leadership during the projected period. This growth can be attributed to the growing partnerships between established corporations in this field and emerging nanomedicine start-ups.

    Additionally, the region's substantial involvement in the industrial sector is attributable to increased R&D spending mixed with governmental backing. An increase in research funding and a rise in demand for life-threatening illness prophylaxis in the United States is what is fueling the market's expansion. The country also has a substantial number of manufacturing companies engaged in strategic nanomedicine endeavors.

    Want to know which region offers the best growth opportunities? Register Here

    Key Players

    The following are the key players in the Nanomedicine Market (arranged alphabetically)

    • Abbott Laboratories
    • Arrowhead Pharmaceuticals, Inc.
    • Celgene Corporation
    • Combi Matrix Corporation
    • General Electric
    • Johnson & Johnson Services, Inc.
    • Mallinckrodt Pharmaceuticals
    • Merck & Co., Inc.
    • Nano spectra Biosciences, Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.

    Note: The above list does not necessarily include all the top players in the market.

    Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    in-depth Analysis of the Nanomedicine Market

    How lucrative is the future?

    The market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and Forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

    We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research:

    Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The nanomedicine market size is likely to reach US$ 523 billion in 2028.

    The nanomedicine market is expected to grow at a CAGR of 12.91% during 2022-2028.

    The market for nanomedicines is anticipated to be driven by the development and commercialization of procedures that have the potential to considerably improve drug administration and disease management.

    With the highest share in 2021, North America dominated the global industry. The region is anticipated to maintain its leadership during the projected period.

    The major players in the nanomedicine market are Abbott Laboratories, Arrowhead Pharmaceuticals, Inc., Celgene Corporation, Combi Matrix Corporation, General Electric, Johnson & Johnson Services, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Nano spectra Biosciences, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd.

    The market is studied from 2016-2028.